CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 19 enrolled
Drug / intervention
sunitinib and rapamycin (Drug will be held)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00555256
NCT00555256Phase 1Completed
CompareCT.gov

A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)

Washington University School of Medicine·interventional·Posted Nov 8, 2007·Updated May 6, 2016

In Brief

A Phase 1 clinical trial evaluating sunitinib and rapamycin (Drug will be held) for Non-Small Cell Lung Cancer. Completed, enrolled 19 participants across 1 site.

Detailed Summary

To define the optimal dose of sunitinib when given in combination with rapamycin 2mg. To determine the maximum tolerated dosage of sunitinib and rapamycin given in this fashion. To determine the how many times and how severe other toxicities of this combination therapy. To determine how quickly the patient(s) will respond the the drug, overall survival and time to progression for this combination therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 8, 2007
Enrollment StartNov 1, 2007
Primary CompletionFeb 1, 2010
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.7 years ago

Interventions

sunitinib and rapamycin (Drug will be held)drug

Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.